Ornithine transcarbamylase vector ( DrugBank: Ornithine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 251 | Urea cycle disorder | 1 |
251. Urea cycle disorder
Clinical trials : 54 / Drugs : 61 - (DrugBank : 15) / Drug target genes : 3 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00004307 (ClinicalTrials.gov) | December 1999 | 18/10/1999 | Study of Treatment and Metabolism in Patients With Urea Cycle Disorders | Therapeutic and Metabolic Studies of Urea Cycle Disorders: Part A: Nitrogen Flux and Ureagenesis; Part B (Closed): Phase I Adenovirus Vector-Mediated Gene Therapy for Ornithine Transcarbamylase Deficiency | Amino Acid Metabolism, Inborn Errors | Behavioral: Protein and calorie controlled diet;Genetic: Ornithine transcarbamylase vector | National Center for Research Resources (NCRR) | Baylor College of Medicine | Recruiting | 6 Months | 64 Years | Both | 66 | Phase 1 | United States |